Neonatal herpes simplex virus infections: is there a role for immunoglobulin in disease prevention and therapy?
- PMID: 8072834
Neonatal herpes simplex virus infections: is there a role for immunoglobulin in disease prevention and therapy?
Abstract
Neonatal herpes simplex virus infections cause significant morbidity and mortality among infected babies, despite the availability of antiviral therapy. These infections manifest in one of three forms: skin, eye, and mouth involvement; encephalitis; or disseminated infection. The latter two forms of disease account for more than 50% of babies with neonatal herpes and are associated with mortality and severe morbidity rates that exceed 75% in infected children. Thus future therapeutic efforts must be directed toward improved disease outcome. One such effort is the evaluation of immunoglobulin products (humanized monoclonal antibodies, human monoclonal antibodies and hyperimmune globulin) as part of a concomitant therapeutic regimen for babies with encephalitis and disseminated infection. The logic for such an approach becomes especially apparent for babies with disseminated disease because little transplacental maternal antibody is received at the time of birth. Thus concomitant administration of antiviral therapy with antibody may improve disease outcome.
Similar articles
-
Therapeutic challenges of neonatal herpes simplex virus infection.Scand J Infect Dis Suppl. 1985;47:97-106. Scand J Infect Dis Suppl. 1985. PMID: 3868027
-
Neonatal herpes simplex virus infections: pathogenesis and therapy.Pathol Biol (Paris). 1992 Sep;40(7):729-34. Pathol Biol (Paris). 1992. PMID: 1336158 Review.
-
Neonatal herpes: what have we learned.Semin Pediatr Infect Dis. 2005 Jan;16(1):7-16. doi: 10.1053/j.spid.2004.09.006. Semin Pediatr Infect Dis. 2005. PMID: 15685144 Review.
-
A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group.N Engl J Med. 1991 Feb 14;324(7):444-9. doi: 10.1056/NEJM199102143240703. N Engl J Med. 1991. PMID: 1988829 Clinical Trial.
-
Neonatal herpes simplex virus infections. Presentation and management.J Reprod Med. 1986 May;31(5 Suppl):426-32. J Reprod Med. 1986. PMID: 3522894 Clinical Trial.
Cited by
-
Trivalent Glycoprotein Subunit Vaccine Prevents Neonatal Herpes Simplex Virus Mortality and Morbidity.J Virol. 2020 May 18;94(11):e02163-19. doi: 10.1128/JVI.02163-19. Print 2020 May 18. J Virol. 2020. PMID: 32188735 Free PMC article.
-
Herpes simplex and varicella-zoster virus infections during pregnancy: current concepts of prevention, diagnosis and therapy. Part 1: herpes simplex virus infections.Med Microbiol Immunol. 2007 Jun;196(2):89-94. doi: 10.1007/s00430-006-0031-0. Epub 2006 Dec 13. Med Microbiol Immunol. 2007. PMID: 17165093 Review.
-
Herpes Simplex Virus Type 2 Is More Difficult to Neutralize by Antibodies Than Herpes Simplex Virus Type 1.Vaccines (Basel). 2020 Aug 27;8(3):478. doi: 10.3390/vaccines8030478. Vaccines (Basel). 2020. PMID: 32867086 Free PMC article.
-
Macrophages and cytokines in the early defence against herpes simplex virus.Virol J. 2005 Aug 3;2:59. doi: 10.1186/1743-422X-2-59. Virol J. 2005. PMID: 16076403 Free PMC article. Review.
-
[Infections with herpes simplex and varicella-zoster viruses during pregnancy].Hautarzt. 2006 Mar;57(3):207-12, 214-6. doi: 10.1007/s00105-006-1105-z. Hautarzt. 2006. PMID: 16514526 Review. German.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical